PubMed Health⌕ Search

Biomedical subjects

A Griffiths

Publications and source records attributed to A Griffiths.

95 records · Page 6Linked to original sources
PubMedDate not supplied

Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease.

BACKGROUND: The effect of nasogastric feeding with high- and low-fat, peptide-based diets on body composition and disease activity was studied in adolescents with active Crohn's disease. METHODS: Fourteen patients with active Crohn's disease (12 to 17 years) were fed exclusively through nasogastric feedings with two isocaloric, isonitrogenous, peptide-based diets, either with low- or high-fat content, for 3 weeks each in a randomized manner then were "crossed over" to the other diet for another 3 weeks of feeding. At the end of each 3-week period, urine and stools were collected for 72 hours for measuring energy absorption and nitrogen utilization (n = 6). Weight, height, triceps skin folds, fat free body mass, and disease activity were also monitored (n = 14). RESULTS: There was no difference in any parameter of energy absorption or nitrogen utilization between the two formulas irrespective of the order in which they were administered. The changes in nutritional parameters were also comparable with both formulas. There was a significant increase in weight, fat free body mass and triceps skinfold thickness during both the 3-week periods of feeding (p < .05). This was accompanied by a significant reduction in the pediatric Crohn's disease activity index (p < .05). CONCLUSIONS: Peptide-based diets may be useful in restoring the fat free body mass and improving the disease activity in patients with Crohn's disease. A high fat (high medium-chain triglycerides) diet did not offer any nutritional advantage over a similar but low-fat diet. The improvement in disease activity during feeding with a low-fat diet was comparable to that with a high-fat diet. The improvement in disease activity seems to be associated with improvement in lean body mass irrespective of the type of diet used to achieve it.

Adolescent↗
PubMedDate not supplied

Quality control of drug assays.

Previously published work relating to quality control of drug assays has dealt mainly with interlaboratory comparisons. It is suggested that participants in external quality assessment schemes wil derive the maximum benefit from their participation if a suitable intralaboratory quality control scheme is established. Such a scheme should be capable of providing estimates of within- and between-batch imprecision over the concentration range for which the assay is used and give an indication of the development of systematic error (relative to previous performance). A scheme using serum pools at 3 concentrations, each to be analysed at least in duplicate, is recommended. Adaptations of this scheme, to be used when the number of patient samples per batch does not justify this number of control samples, are discussed in relation to various analytical situations. A ratio of 1 control sample to 10 patient samples is considered reasonable. The interpretation of results from external quality assessment schemes using performance indices, graphical assessment of 'bias' and standard deviation interval (SDI = bias divided by standard deviation) and the statistical evaluation of proportional and additive error by linear regression (least squares) analysis is discussed. In some cases it has been possible, from the results of interlaboratory studies, to show that a particular method will not generally give satisfactory results when compared either with other currently available methods, e.g. UV - spectrophotometric methods for phenobarbitone, phenytoin, carbamazepine and theophylline, or on the grounds of clinical requirements, e.g. doubling dilution broth techniques for gentamicin. Improvement in intralaboratory reproducibility would facilitate the identification of technical factors contributing to interlaboratory variation.

Animals↗
PubMedDate not supplied

The breast tumour-associated epithelial mucins and the peanut lectin binding urinary mucins are coded by a single highly polymorphic gene locus 'PUM'.

A family of mucin-type glycoproteins, present in human urine, is coded by a single highly polymorphic gene locus PUM. We have previously shown that these glycoproteins carry epitopes recognized by a series of monoclonal antibodies, many of which were raised to the human milk-fat globule membrane, and which bind to a wide variety of carcinomas and certain normal epithelia. Here we show that in the normal human mammary gland, and in breast cancers the epitopes are present on the same family of molecules as that found in urine. Thus the genetically determined variation at the PUM locus accounts for much of the electrophoretic heterogeneity of the mucin-type glycoproteins present in breast cancer and serum from breast cancer patients that has been reported previously. Knowledge of this normal inherited polymorphism is essential to the interpretation of possible changes to these molecules in malignancy.

Antigens, Neoplasm↗